T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6.

[1]  W. Oyen,et al.  Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients , 2011, International journal of cancer.

[2]  J. Yang,et al.  Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor. , 2011, Blood.

[3]  M. Carini,et al.  Frequency of regulatory T cells in peripheral blood and in tumour‐infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma , 2011, BJU international.

[4]  E. Tartour,et al.  A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients , 2010, Journal of immunotherapy.

[5]  H. Radzun,et al.  Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma , 2010, BMC Cancer.

[6]  W. Xu,et al.  Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. , 2010, Clinical immunology.

[7]  U. Panzer,et al.  CCR6 recruits regulatory T cells and Th17 cells to the kidney in glomerulonephritis. , 2010, Journal of the American Society of Nephrology : JASN.

[8]  T. Blankenstein,et al.  T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy , 2010, Clinical Cancer Research.

[9]  Hans-Georg Rammensee,et al.  Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. , 2009, Cancer research.

[10]  A. Chang,et al.  FOXP3 defines regulatory T cells in human tumor and autoimmune disease. , 2009, Cancer research.

[11]  G. Kristiansen,et al.  Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. , 2009, European journal of cancer.

[12]  N. Marcussen,et al.  Increased Intratumoral FOXP3-positive Regulatory Immune Cells during Interleukin-2 Treatment in Metastatic Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[13]  M. Merino,et al.  FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. , 2008, Blood.

[14]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[15]  J Philip McCoy,et al.  Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. , 2008, The Journal of clinical investigation.

[16]  D. Adams,et al.  Expression and function of T cell homing molecules in Hodgkin’s lymphoma , 2008, Cancer Immunology, Immunotherapy.

[17]  S. Rosenberg.  Interleukin 2 for patients with renal cancer , 2007, Nature Clinical Practice Oncology.

[18]  M. Cybulsky,et al.  Getting to the site of inflammation: the leukocyte adhesion cascade updated , 2007, Nature Reviews Immunology.

[19]  P. Stern,et al.  Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival , 2007, Cancer Immunology, Immunotherapy.

[20]  T. Huizinga,et al.  Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells , 2007, European journal of immunology.

[21]  F. Garrido,et al.  Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. , 2006, Tissue antigens.

[22]  F. Ito,et al.  Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1‐type immune response , 2006, Cancer science.

[23]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[24]  H. Ishikura,et al.  Up‐regulation of the interferon γ (IFN‐γ)‐inducible chemokines IFN‐inducible T‐cell α chemoattractant and monokine induced by IFN‐γ and of their receptor CXC receptor 3 in human renal cell carcinoma , 2005 .

[25]  H. Ishikura,et al.  Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma. , 2005, Cancer.

[26]  A. Concha,et al.  Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas , 2005, Cancer Immunology, Immunotherapy.

[27]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[28]  S. Horita,et al.  High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. , 2004, The Journal of urology.

[29]  F. Marincola,et al.  Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. , 2002, Human gene therapy.

[30]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[31]  J. Finke,et al.  The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. , 1998, Journal of immunology.

[32]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[33]  P. Schellhammer,et al.  Spontaneous regression of metastatic renal cell carcinoma. , 1982, Urology.